Editorial board disclosure policy

 

Journal of Endocrinology and Journal of Molecular Endocrinology Disclosure Policy

 
(Last updated March 2022)
 
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
 
The following competing interests were disclosed:
 
Professor Simak Ali
Professor Ali owns shares in Carrick Therapeutics Ltd and has received royalties for a patent that has been licensed to Carrick Therapeutics Ltd. He has also received consultancy money from Carrick Therapeutics Ltd in 2017 and received a MRC PhD studentship jointly with Astra Zeneca (2018–2020).
 
Professor Ian Bird
Professor Bird has funding from NIH, mostly T32 training grants, CoI as a sample collection core PI on a Pediatric network study (ECHO Coordination study). He is currently leading a P01 application to NHLBI on preeclamptic pregnancy. He reviews for NIH, principally at NICHD but sometimes NHLBI and NIGMS. Professor Bird is active in Society Reproductive Investigation and Perinatal Research Society, and has held past leadership offices in both. He has a patent in consideration for the use of Conjugated Linoleic Acid to treat preeclampsia.
 
Professor Wendy Bollag
Professor Bollag is listed as an inventor of the following patents: US Patent No 8,808,715 and US Patent No 8,524,692.
 
Dr James Cantley
Dr Cantley is an academic founder and shareholder of Oxstem Beta, a spin out from the University of Oxford seeking to develop new drugs to promote beta cell regeneration during diabetes. Oxstem Beta sponsors some research in the Cantley lab, which is goverened by University processes and a conflict of interest management plan. Dr Cantley has supervised several postdoctoral fellows under the Oxford-Novo Nordisk Fellowship scheme. These fellows are employed by the University of Oxford, but are sponsored by Novo Nordisk; https://www.rdm.ox.ac.uk/work-with-us/novo-nordisk-oxford-fellowships.
 
Professor Colin Farquharson
Professor Farquharson has received personal fees for his work on the HBLB VAC committee.
 
Professor Martin Haluzik
Professor Haluzik is on the advisory panel and has received lecture fees for: Novo Nordisk, Sanofi, Eli Lilly, Novartis, Johnson Johnson, Astra Zeneca and Mundipharma. He is also on the advisory panel for Medtronic and has received lecture fees from Merck.
 
Dr Rebecca Hull
Dr Hull has received research funding from Boehringer Ingelheim.
 
Dr Lenka Maletínská
Dr Maletínská has a license agreement and research grant with Novo Nordisk (2017-2022). She has also been granted the following patents, 2019-2021: Lipidated peptides for lowering blood glucose, US2015/0196651 (granted 15.5.20190), IL 246618 (granted 1.5.2021); Lipidized peptides as neuroprotective agents, US10,751,390 (granted 25.8.2020), IL 248370 (granted 29.2.2020), EP 3149029 (granted 19.6.2019) and CA2.950.416 (granted 2.3.2021).
 
Dr Morag Young
Dr Young has received a research grant from AstraZeneca and NHMRC of Australia, research grants ending Dec 2019. She is also involved with new AstraZeneca MR antagonist for in vitro experimental studies and new Bayer MR antagonist for in vitro experimental studies.
 
The following editors reported no competing interests:
  • Dr Anita Boelen
  • Dr Eugenia Carvalho
  • Professor Barbara Clark
  • Professor Alan J Conley
  • Professor Weiping Han
  • Professor Sean Limesand
  • Dr Raul M Luque
  • Dr Ernesto Podesta
  • Professor Weiping Zhang
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
 
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).